ProQR Therapeutics N.V. Target price 2024 - Analyst rating & recommendation
ProQR Therapeutics N.V. Classifications & Recommendation:
ProQR Therapeutics N.V. Target price
| Target price | $4.28 |
| Course | $1.66 |
| Price potential |
157.90%
register free of charge
|
| Number of estimates | 6 |
|
6 Analysts have issued a price target ProQR Therapeutics N.V. 2025 .
The average ProQR Therapeutics N.V. target price is $4.28.
This is
157.90%
register free of charge
$6.05
264.21%
register free of charge
$2.00
20.76%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend ProQR Therapeutics N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the ProQR Therapeutics N.V. share has an average upside potential 2025 of
157.90%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 7.04 | 23.67 |
| 66.04% | 236.28% | |
| EBITDA margin | -496.88% | -238.20% |
| 68.16% | 52.06% | |
| Net margin | -440.78% | -114.91% |
| 76.16% | 73.93% |
5 Analysts have issued a sales forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. sales estimate is
This results in the following potential growth figures:
1 Analyst has issued an EBITDA forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
1 Analyst has issued a net profit forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -0.38 | -0.33 |
| 60.42% | 13.16% | |
| P/E ratio | negative | |
| EV/Sales | 1.85 |
1 Analysts have issued a ProQR Therapeutics N.V. forecast for earnings per share. The average ProQR Therapeutics N.V. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the ProQR Therapeutics N.V. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
ProQR Therapeutics N.V....
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
